

Curriculum Vitae

Stephanie Thee PD, Dr. med., PhD
d.o.b. June 12th, 1978, in Eutin, Germany

University Education

2023 Habilitation Pediatrics, Charité – Universitätsmedizin Berlin
2008 Doctorate Medicine, Charité – Universitätsmedizin Berlin
1999-2006 Studies of Medicine, J.W.-Goethe-Universität, Frankfurt/Main and Charité – Universitätsmedizin Berlin

Scientific Career

Since 2025 Head of Primary Ciliary Dyskinesia Clinic, Charité - Universitätsmedizin Berlin
Since 2024 Lead Study Physician „CoughMon”, international investigator initiated trial, Vertex Pharmaceuticals independent grant
Since 2024 Core member of ECFS working group on pulmonary exacerbations in CF
Since 2023 Core member of ECFS working group on telehealth in CF
Since 2023 Advanced clinician scientist at the Berlin Institute of Health (BIH)
Since 2022 Consultant in Pediatrics, Charité - Universitätsmedizin Berlin
Since 2022 Co-Chair of the European Respiratory Society Clinical Research Collaboration: "Anti-Microbial Resistance in Lung infections (AMR-Lung)".
Principal investigator “Unmask TB” multicentre observational study Charité Universitätsmedizin, Berlin, Germany
Since 2020 Lead Study Physician "conneCT CF- Coaching and Telemonitoring for Patients with Cystic Fibrosis" Innovation Fund Projekt
Co-Investigator "Cerebral imaging in tuberculous meningitis" observational study Charité Universitätsmedizin, Berlin, Germany.
2014 - 2022 Clinical and Research Fellow in Pediatrics, Charité – Universitätsmedizin Berlin
2013 - 2015 PhD: Pharmacokinetics and safety of first- and second-line antituberculosis drugs in children. Stellenbosch University, South Africa
2009 - 2010 Postdoctoral Fellow Desmond Tutu TB Centre, Stellenbosch University, Cape Town, South Africa,
2007 – 2014 Resident in Pediatrics, Pediatric Clinic, DRK Kliniken Westend, Berlin (Director: PD Dr. A. von Moers)
2006 - 2007 Residency in Pediatrics, University of Rostock (Director Prof. Dr. M. Peuster)

Awards and Honors

2016 HD Brede Award for Tuberculosis Research

Citation Record

Total citations: 3,706; h-index:29; h-index since 2021: 22 (Google Scholar March 6th, 2026)

Top-10 selected Publications

Halle, O., Graeber, S. Y., Kotsendorn, J., Kessemeier, C., Falke, J. N., Schwabe, J., Schütz, K., Pallenberg, S. T., Dalferth, R., Grychtol, R., Ringshausen, F. C., Stahl, M., Thee, S., Roehmel, J. F., Syunyaeva, Z., Duerr, J., Chung, J., Hirtz, S., Uselmann, T., Kühbandner, I., ... Dittrich, A. M. (2025). Reduction of systemic inflammation by elexacaftor/tezacaftor/ivacaftor correlates with lung function improvement in cystic fibrosis. *The European respiratory journal*, 66(6), 2500150.
<https://doi.org/10.1183/13993003.00150-2025>

Burn, G. L., Raisch, T., Tacke, S., Winkler, M., Prumbaum, D., **Thee, S.**, Gimber, N., Raunser, S., & Zychlinsky, A. (2025). Myeloperoxidase transforms chromatin into neutrophil extracellular traps. *Nature*, 647(8090), 747–756. <https://doi.org/10.1038/s41586-025-09523-9>

Stahl, M., Dohna, M., Graeber, S. Y., Sommerburg, O., Renz, D. M., Pallenberg, S. T., Voskrebenezv, A., Schütz, K., Hansen, G., Doellinger, F., Steinke, E., **Thee, S.**, Röhmel, J., Barth, S., Rückes-Nilges, C., Berges, J., Hämmerling, S., Wielpütz, M. O., Naehrlich, L., Vogel-Claussen, J., ... Dittrich, A. M. (2024). Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or two F508del alleles. *The European respiratory journal*, 64(3), 2400004. <https://doi.org/10.1183/13993003.00004-2024>

Meiwes, L., Kontsevaya, I., Chesov, D., Kulçikaia, S., Dreyer, V., Hillemann, D., Dlamini, Q., Williams, C., Barer, M., Brinkmann, F., Krüger, R., **Thee, S.**, Kay, A., Mandalakas, A. M., & Lange, C. (2024). Whispers in the Wind: Face Mask Sampling for Mycobacterium tuberculosis Detection in Children With Pulmonary Tuberculosis. *The Journal of infectious diseases*, 230(6), 1510–1517. <https://doi.org/10.1093/infdis/jiae282>

Pioch, C. O., Ziegahn, N., Allomba, C., Busack, L. M., Schnorr, A. N., Tosolini, A., Fuhlrott, B. R., Zagkla, S., Othmer, T., Syunyaeva, Z., Graeber, S. Y., Yoosefi, M., **Thee, S.**, Steinke, E., Röhmel, J., Mall, M. A., & Stahl, M. (2024). Elexacaftor/tezacaftor/ivacaftor improves nasal nitric oxide in patients with cystic fibrosis. *Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society*, 23(5), 863–869. <https://doi.org/10.1016/j.jcf.2024.03.003>

Schaupp, L., Addante, A., Völler, M., Fentker, K., Kuppe, A., Bardua, M., Duerr, J., Piehler, L., Röhmel, J., **Thee, S.**, Kirchner, M., Ziehm, M., Lauster, D., Haag, R., Gradzielski, M., Stahl, M., Mertins, P., Boutin, S., Graeber, S. Y., & Mall, M. A. (2023). Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis. *The European respiratory journal*, 62(2), 2202153. <https://doi.org/10.1183/13993003.02153-2022>

Gafar, F., Wasmann, R. E., McIlleron, H. M., Aarnoutse, R. E., Schaaf, H. S., Marais, B. J., Agarwal, D., Antwi, S., Bang, N. D., Bekker, A., Bell, D. J., Chabala, C., Choo, L., Davies, G. R., Day, J. N., Dayal, R., Denti, P., Donald, P. R., Engidawork, E., Garcia-Prats, A. J., ... Global Collaborative Group for Meta-Analysis of Paediatric Individual Patient Data in Pharmacokinetics of Anti-TB Drugs (2023). Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis. *The European respiratory journal*, 61(3), 2201596. <https://doi.org/10.1183/13993003.01596-2022>

Thee, S., Basu Roy, R., Blázquez-Gamero, D., Falcón-Neyra, L., Neth, O., Noguera-Julian, A., Lillo, C., Galli, L., Venturini, E., Buonsenso, D., Götzinger, F., Martinez-Alier, N., Velizarova, S., Brinkmann, F., Welch, S. B., Tsolia, M., Santiago-García, B., Schilling, R., Tebruegge, M., Krüger, R., ... ptbnet TB Meningitis Study Group (2022). Treatment and Outcome in Children With Tuberculous Meningitis: A Multicenter Pediatric Tuberculosis Network European Trials Group Study. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*, 75(3), 372–381. <https://doi.org/10.1093/cid/ciab982>

Radtke, K. K., Hesselring, A. C., Winckler, J. L., Draper, H. R., Solans, B. P., **Thee, S.**, Wiesner, L., van der Laan, L. E., Fourie, B., Nielsen, J., Schaaf, H. S., Savic, R. M., & Garcia-Prats, A. J. (2022). Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*, 74(8), 1372–1381. <https://doi.org/10.1093/cid/ciab641>

Basu Roy, R., **Thee, S.**, Blázquez-Gamero, D., Falcón-Neyra, L., Neth, O., Noguera-Julian, A., Lillo, C., Galli, L., Venturini, E., Buonsenso, D., Götzinger, F., Martinez-Alier, N., Velizarova, S., Brinkmann, F.,

Welch, S. B., Tsolia, M., Santiago-Garcia, B., Krüger, R., Tebruegge, M., & ptbnet TB Meningitis Study Group (2020). Performance of immune-based and microbiological tests in children with tuberculosis meningitis in Europe: a multicentre Paediatric Tuberculosis Network European Trials Group (ptbnet) study. *The European respiratory journal*, 56(1), 1902004. <https://doi.org/10.1183/13993003.02004-2019>